EMR data to increase strength of Pharmatech’s current AccessPPM program

June 18, 2014 - PRLog -- Pharmatech has officially entered the "big data" arena in the world of clinical oncology, through its AccessPPM molecular diagnostic protocol and its partnership with Paradigm.

Pharmatech and Paradigm are joining clinical EMR data with comprehensive next generation sequencing to provide new insight into patient treatment and outcomes from a molecular understanding. Earlier in the year, Pharmatech launched AccessPPM, a registry designed to collect EMR data and an extensive biomarker profile to help match patients with the next generation of clinical trials – of highly targeted anti-cancer medicines which may provide a significantly brighter future for cancer patients. The AccessPPM protocol is commencing with 55 sites across the US, then will expand beyond Pharmatech's entire research network of 345 cancer centers across the US.

Another major benefit of AccessPPM, is the registry of case matched molecular data it collects.  This will yield significant value to pharmaceutical companies, to better understand how their drugs interact with and alter tumors within the context of specific biomarkers.

According to Rob Bohacs, CEO, "This could yield significant clues to big pharma to where their drugs are most effective, if they are being used off label, and the level of efficacy they may be realizing in populations that are stratified by biomarkers. In addition, we may see alterations at a genetic level that may not necessary yield clinical efficacy, but may transform the genetic structure of the tumor where a secondary drug then could be more effective".

Bohacs believes it's truly a special time in oncology and one of the most powerful tools may be data and computing power.

About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) exclusively focused on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in the spectrum of patient treatment options.

About Paradigm

Paradigm is a non-profit corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing additional information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s diagnostic test provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market.